Combining Glipizide and Synjardy in Diabetes Management

Pharmacological Considerations

The American College of Cardiology recommends that glipizide and Synjardy can be safely used together, but dose adjustments and careful monitoring are necessary to avoid hypoglycemia 1, 2
Glipizide is a second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells 3
The combination of glipizide, empagliflozin, and metformin provides multiple mechanisms to control blood glucose: glipizide increases insulin secretion 4, empagliflozin promotes urinary glucose excretion 5, and metformin decreases hepatic glucose production and improves insulin sensitivity 5

The American College of Cardiology suggests that when adding Synjardy to glipizide therapy, there is an increased risk of hypoglycemia that requires careful management 2, 6
Consider reducing the glipizide dose by 50% when initiating Synjardy to minimize hypoglycemia risk 2
Monitor blood glucose levels closely, especially during the initial titration period 4
Metformin component of Synjardy should not be used in patients with eGFR <30 mL/min/1.73m² 7 or serum creatinine ≥1.5 mg/dL in men or ≥1.4 mg/dL in women 3
Empagliflozin efficacy is dependent on renal function; reduced glucose-lowering effect is seen with declining kidney function 5
Glipizide is preferred over other sulfonylureas in renal impairment as it does not have active metabolites 3, 4

Monitor renal function at least annually if eGFR ≥60 mL/min/1.73m² 7 and every 3-6 months if eGFR 30-59 mL/min/1.73m² 7
Assess for signs and symptoms of hypoglycemia, especially during initial combination therapy 2
Monitor for potential side effects, including genital mycotic infections from empagliflozin 8 and risk of euglycemic diabetic ketoacidosis from empagliflozin 8

Start with standard doses of glipizide and consider reducing the dose when adding Synjardy 2
Educate patients about signs and symptoms of hypoglycemia 4, need for regular blood glucose monitoring 4, and potential for genital mycotic infections with SGLT2 inhibitor component 8
Temporarily withhold Synjardy during periods of severe illness 5, dehydration 5, surgery 7, or reduced oral intake 7

In patients with established cardiovascular disease or heart failure, the empagliflozin component of Synjardy offers cardiovascular benefits 9
In patients with chronic kidney disease, glipizide is preferred over other sulfonylureas, but dose adjustments may be needed 3, 4
In elderly patients, start with lower doses of both medications and monitor more frequently for hypoglycemia 4